# Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-bosutinib-ski-606-in-patients-with-chronic-phase-cp-ph/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jörge E. Cortes,Hagop M. Kantarjian,Dong Wook Kim,H. Jean Khoury,Anna Turkina,Zhixiang Shen,Tim H. Brümmendorf,Mammen Chandy,Steven Arkin,Carlo Gambacorti‐Passerini |
| Citations | 49 |
| DOI | 10.1182/blood.v112.11.1098.1098 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2530270604 |
| Type | article |
| Year | 2008 |

## Paper authors

- [Dong Wook Kim](https://scholariq.org/researchers/dong-wook-kim/)

## Paper journal

- [Blood](https://scholariq.org/journals/blood/)

## Paper primary topic

- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)

## Paper topics

- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Eosinophilic Disorders and Syndromes](https://scholariq.org/topics/eosinophilic-disorders-and-syndromes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.